Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel Free NGNE Stock Alerts

Neurogene (NGNE) News Today

Neurogene logo
$28.98 +0.76 (+2.71%)
Closing price 03:59 PM Eastern
Extended Trading
$29.01 +0.03 (+0.09%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NGNE Latest News

We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth
May 5 at 9:58 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/think-neurogene-nasdaq-ngne-afford-113758473.html
Jennison Associates LLC Increases Holdings in Neurogene Inc. $NGNE
May 3 at 6:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jennison-associates-llc-increases-holdings-in-neurogene-inc-ngne-2026-05-03/
Neurogene (NASDAQ:NGNE) Stock Rating Upgraded by Guggenheim
May 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/neurogene-nasdaqngne-stock-rating-upgraded-by-guggenheim-2026-05-01/
Neurogene (NGNE) Expected to Announce Quarterly Earnings on Thursday
April 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/neurogene-ngne-expected-to-announce-quarterly-earnings-on-thursday-2026-04-30/
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of "Moderate Buy" from Analysts
April 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/neurogene-inc-nasdaqngne-receives-consensus-rating-of-moderate-buy-from-analysts-2026-04-29/
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
April 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/neurogene-announces-upcoming-presentation-therapeutic-113000678.html
Neurogene (NASDAQ:NGNE) Shares Up 0.1% - Here's What Happened
April 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/neurogene-nasdaqngne-shares-up-01-heres-what-happened-2026-04-28/
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
April 20, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260420578021/en/Neurogene-Appoints-Christy-Shafer-as-Chief-Commercial-Officer-and-Christine-Mikail-J.D.-to-Board-of-Directors/
Neurogene Inc.
April 8, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/NGNE
Neurogene (NASDAQ:NGNE) Given New $180.00 Price Target at Canaccord Genuity Group
April 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/neurogene-nasdaqngne-given-new-18000-price-target-at-canaccord-genuity-group-2026-04-06/
Neurogene (NGNE) price target increased by 37.29% to 82.62
March 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/neurogene-ngne-price-target-increased-by-3729-to-8262/ar-AA1ZyYk8
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Neurogene (NGNE)
March 26, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PVLA-Q/pressreleases/947989/analysts-offer-insights-on-healthcare-companies-palvella-therapeutics-pvla-and-neurogene-ngne/
Neurogene: Q4 Earnings Snapshot
March 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/neurogene-q4-earnings-snapshot-114632528.html
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
March 24, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260324872399/en/neurogene-reports-full-year-2025-financial-results-and-highlights-recent-updates/
Neurogene (NASDAQ:NGNE) CFO Sells $84,176.45 in Stock
March 18, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ngne-insider-buying-and-selling-2026-03-18/
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
March 11, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260311342818/en/neurogene-to-participate-in-stifel-2026-virtual-cns-forum/
Neurogene: Stock Soars On FDA Designation For Rett Gene Therapy - I'd Remain Cautious
February 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4876522-neurogene-stock-soars-on-fda-designation-for-rett-gene-therapy-remain-cautious
Neurogene stock surges 30% on FDA breakthrough therapy status
February 26, 2026  |  uk.investing.comhttps://uk.investing.com/news/stock-market-news/neurogene-stock-surges-30-on-fda-breakthrough-therapy-status-93CH-4529954
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
February 26, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260226883579/en/neurogene-announces-fda-breakthrough-therapy-designation-for-ngn-401-gene-therapy-for-rett-syndrome/
Neurogene Insider Trading Activity | NASDAQ:NGNE | Benzinga
January 31, 2026  |  benzinga.comhttps://www.benzinga.com/quote/NGNE/insider-trades
LifeSci Capital initiates coverage of Neurogene (NGNE) with outperform recommendation
January 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/lifesci-capital-initiates-coverage-of-neurogene-ngne-with-outperform-recommendation/ar-AA1V3B1g
Neurogene traite plusieurs patients dans son essai de thérapie génique contre le syndrome de Rett
January 12, 2026  |  fr.investing.comhttps://fr.investing.com/news/company-news/neurogene-traite-plusieurs-patients-dans-son-essai-de-therapie-genique-contre-le-syndrome-de-rett-93CH-3216473
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
January 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260112556591/en/neurogene-announces-recent-achievements-and-anticipated-2026-key-milestones-for-ngn-401-a-potential-best-in-class-gene-therapy-for-rett-syndrome/
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260105973729/en/Neurogene-to-Participate-in-the-44th-Annual-J.P.-Morgan-Healthcare-Conference/
Neurogene: From Speculation To Execution With NGN-401
November 24, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4847000-neurogene-stock-from-speculation-to-execution-with-ngn-401
Neurogene Inc. Reports Q3 2025 Financial Results
November 18, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/neurogene-inc-reports-q3-2025-financial-results/ar-AA1QEHNB
Neurogene (NGNE) Price Target Increased by 11.85% to 60.18
November 18, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/neurogene-ngne-price-target-increased-by-1185-to-6018/ar-AA1QDE2G
Neurogene Announces Positive Interim Data for NGN-401
November 14, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/neurogene-announces-positive-interim-data-for-ngn-401/ar-AA1QkLuj
Neurogene Reports Positive Interim Results for Rett Syndrome Gene Therapy
November 13, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neurogene-reports-positive-interim-results-for-rett-syndrome-gene-therapy?utm_source=marketbeat.com&utm_medium=referral
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
November 13, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251113825408/en/neurogene-reports-third-quarter-2025-financial-results-and-highlights-recent-updates/
Neurogene Inc. (NGNE) Presents at Stifel 2025 Healthcare Conference Transcript
November 12, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4842763-neurogene-inc-ngne-presents-at-stifel-2025-healthcare-conference-transcript
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
November 12, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251112150450/en/neurogene-reports-positive-interim-data-in-pediatric-cohort-from-ngn-401-gene-therapy-trial-for-rett-syndrome/
Neurogene doses first patient in NGN-401 clinical trial
November 6, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/neurogene-doses-first-patient-in-ngn-401-clinical-trial/ar-AA1PWGIs
Neurogene Begins Dosing in Rett Syndrome Trial
November 6, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/neurogene-begins-dosing-in-rett-syndrome-trial/ar-AA1PWotj
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
November 6, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/neurogene-announces-first-participant-dosed-123000884.html
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
November 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251106135659/en/neurogene-announces-first-participant-dosed-in-embolden%e2%84%a2-registrational-trial-of-ngn-401-gene-therapy-for-rett-syndrome/
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 5, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/neurogene-announces-inducement-grant-under-210100430.html
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 5, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251105674125/en/neurogene-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4/
HC Wainwright & Co. Maintains Neurogene (NGNE) Buy Recommendation
October 31, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/hc-wainwright-co-maintains-neurogene-ngne-buy-recommendation/ar-AA1PABCb
Neurogene price target raised to $65 from $45 at H.C. Wainwright
October 31, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/neurogene-price-target-raised-to-65-from-45-at-hc-wainwright/ar-AA1PznUo
Neurogene (NGNE) Price Target Increased by 11.29% to 53.80
October 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/neurogene-ngne-price-target-increased-by-1129-to-5380/ar-AA1Prp87
HC Wainwright & Co. Reiterates Neurogene (NGNE) Buy Recommendation
October 10, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/hc-wainwright-co-reiterates-neurogene-ngne-buy-recommendation/ar-AA1Ocg5e
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
October 9, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/neurogene-announces-positive-regulatory-ngn-110000519.html
Neurogene Completes FDA Talks for Rett Syndrome Trial
October 9, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neurogene-completes-fda-talks-for-rett-syndrome-trial?utm_source=marketbeat.com&utm_medium=referral
Neurogene Headed to Medicines Conference
October 8, 2025  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/21805/Neurogene-Headed-to-Medicines-Conference
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
October 8, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/neurogene-participate-h-c-wainwright-113000096.html
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 3, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251003885885/en/neurogene-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright
October 2, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/neurogene-looks-deeply-undervalued-after-taysha-news-says-hc-wainwright/ar-AA1NL7HW
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 5, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250905376668/en/neurogene-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome
August 14, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NGNE/pressreleases/34092867/neurogene-advances-ngn-401-gene-therapy-for-rett-syndrome/
Get Neurogene News Delivered to You Automatically

Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NGNE Media Mentions By Week

NGNE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NGNE
News Sentiment
▼
0.88

0.59
▲
Average
Medical
News Sentiment

NGNE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NGNE Articles
This Week
▼
6

2
▲
NGNE Articles
Average Week

Get the Latest News and Ratings for NGNE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Neurogene and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
Headlines Tools

This page (NASDAQ:NGNE) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel